How can Mira be helpful for patients with EDS/POTS/MCAS?Updated a month ago

For patients with EDS, POTS, or MCAS, hormone fluctuations can significantly influence symptom burden — including autonomic instability, mast cell reactivity, fatigue, pain, and inflammatory responses. Many of these patients report heightened hormonal sensitivity, making pattern recognition particularly valuable.

Mira can help identify whether symptoms are phase-specific — for example, worsening in the luteal phase when progesterone rises, during estrogen shifts, or around ovulation. It also allows clinicians to detect ovulatory instability, anovulatory cycles, or fluctuating estrogen patterns that may contribute to symptom variability.

By tracking hormone patterns longitudinally, clinicians can anticipate higher-risk times in the cycle and proactively adjust hydration strategies, antihistamine support, training load, recovery protocols, or other individualized interventions. This shifts care from reactive symptom management to proactive cycle-informed planning.

For patients who are especially sensitive to hormonal changes, having objective data can also validate their experience and guide more precise, incremental treatment adjustments over time.